EUR 2.66
(1.33%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 18.49 Million EUR | -10.75% |
2022 | 20.72 Million EUR | 22.8% |
2021 | 16.87 Million EUR | 27.04% |
2020 | 13.28 Million EUR | 25.93% |
2019 | 10.54 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.1 Million EUR | 2.86% |
2024 Q3 | 2.79 Million EUR | -9.9% |
2024 Q1 | 3.24 Million USD | -32.73% |
2023 Q4 | 4.48 Million EUR | 6.98% |
2023 FY | 18.49 Million EUR | -10.75% |
2023 Q3 | 4.18 Million EUR | -13.79% |
2023 Q2 | 4.85 Million EUR | -5.29% |
2023 Q1 | 5.13 Million EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | 20.72 Million EUR | 22.8% |
2021 FY | 16.87 Million EUR | 27.04% |
2020 FY | 13.28 Million EUR | 25.93% |
2019 FY | 10.54 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Atrys Health, S.A. | 143.61 Million EUR | 87.12% |
Biotechnologies Assets SA | 840.45 Thousand EUR | -2100.858% |
Pharma Mar, S.A. | 152.36 Million EUR | 87.86% |
Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 92.969% |